Industry Outlook 2022

The Astellas chief commercial officer discusses the impact that the increase in global and local connectivity has had on commercialization, among other trends.

Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.

Amid shifting operating dynamics in recent years, demands for external expertise have fluctuated—leaving those arrangements that mix innovation and agility likely to win out in pharma decision-making.

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

A Harvard Business School Healthcare Alumni Association Q&A with Jeremy Goldberg of Arsenal Capital Partners.

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.